Indegene’s Q4: Revenue Rockets, Profits Pulse Higher, and Shareholders Get a Sweet Pill

Indegene, a life sciences commercialization firm, digital by first, announced strong financials for the quarter and year ended March 31, 2025. The consolidated revenue from operations of the company stands at ₹7.56 billion for the quarter ended March 31, 2025, a growth of 4.9% quarter-on-quarter. Net profit in the quarter was ₹1.18 billion, a sequential growth of 7.2%.

 

In the entire financial FY25, Indegene registered revenue of ₹28.39 billion, which rose 9.6% y-o-y, and net profit of ₹4.07 billion, higher by 20.8% year on year.

 

In a historic verdict for the shareholders, Indegene declared its initial dividend, paying ₹2 per share (100% of face value) for FY25.

 

Management linked the growth to sustained momentum with big and mid-pharma customers, enhanced productivity, and successful automation efforts. The company clocked a robust PAT margin of 15.6% in the quarter.

 

Source: Indegene Press Release